TY - JOUR
T1 - Déjà Vu All over Again
AU - Jokerst, Clinton E.
AU - Panse, Prasad M.
AU - Jensen, Eric A.
AU - Cummings, Kristopher W.
AU - Gotway, Michael B.
N1 - Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
PY - 2020
Y1 - 2020
N2 - In late 2019, an acute, severe lower respiratory tract illness of unknown etiology, linked to contact with a live seafood and animal market, was reported in Wuhan City, Hubei Province, China, subsequently shown to be caused by a novel coronavirus termed the Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV)-2. The infection caused by this virus is referred to as coronavirus disease 2019, or COVID-19. SARS-CoV-2 infects human cells through binding of viral surface spike protein to human angiotensin-converting enzyme 2 receptors, predominantly expressed on Type II alveolar cells, in the lung. SARS-CoV-2 is highly transmissible, and affected patients can transmit the infection while asymptomatic. Patients commonly complain of fever, dry cough, fatigue, myalgias, headache, and dyspnea. Most infected patients have mild disease and recover, with more severe disease and mortality more commonly present in older individuals and patients with comorbidities, such as hypertension, diabetes, and chronic cardiovascular and respiratory conditions. The diagnosis of COVID-19 is typically established through identification of viral nucleic acid at real-time reverse transcriptase polymerase chain reaction on respiratory tract samples. Chest radiography in COVID-19 infection may be normal; when abnormal, patchy areas of lower lobe ground-glass opacity and/or consolidation are seen. Computed tomography is more sensitive than chest radiography for detection of the infection and commonly shows multifocal, bilateral, peripheral, and basal predominant round or oval areas of ground-glass opacity that may subsequently transition to consolidation. Treatment for COVID-19 is currently supportive, with various ongoing trials evaluating a number of potentially therapeutic agents.
AB - In late 2019, an acute, severe lower respiratory tract illness of unknown etiology, linked to contact with a live seafood and animal market, was reported in Wuhan City, Hubei Province, China, subsequently shown to be caused by a novel coronavirus termed the Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV)-2. The infection caused by this virus is referred to as coronavirus disease 2019, or COVID-19. SARS-CoV-2 infects human cells through binding of viral surface spike protein to human angiotensin-converting enzyme 2 receptors, predominantly expressed on Type II alveolar cells, in the lung. SARS-CoV-2 is highly transmissible, and affected patients can transmit the infection while asymptomatic. Patients commonly complain of fever, dry cough, fatigue, myalgias, headache, and dyspnea. Most infected patients have mild disease and recover, with more severe disease and mortality more commonly present in older individuals and patients with comorbidities, such as hypertension, diabetes, and chronic cardiovascular and respiratory conditions. The diagnosis of COVID-19 is typically established through identification of viral nucleic acid at real-time reverse transcriptase polymerase chain reaction on respiratory tract samples. Chest radiography in COVID-19 infection may be normal; when abnormal, patchy areas of lower lobe ground-glass opacity and/or consolidation are seen. Computed tomography is more sensitive than chest radiography for detection of the infection and commonly shows multifocal, bilateral, peripheral, and basal predominant round or oval areas of ground-glass opacity that may subsequently transition to consolidation. Treatment for COVID-19 is currently supportive, with various ongoing trials evaluating a number of potentially therapeutic agents.
KW - COVID-19
KW - coronavirus
KW - crazy paving
KW - emerging infection
KW - ground-glass opacity
UR - http://www.scopus.com/inward/record.url?scp=85091656764&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091656764&partnerID=8YFLogxK
U2 - 10.1097/CPM.0000000000000369
DO - 10.1097/CPM.0000000000000369
M3 - Article
AN - SCOPUS:85091656764
SN - 1068-0640
VL - 27
SP - 118
EP - 122
JO - Clinical Pulmonary Medicine
JF - Clinical Pulmonary Medicine
IS - 4
ER -